Boldine and Laurolitsine Protect against Periodontitis-Associated Bone Loss via RANKL Downregulation

T-cell frequencies between treated and untreated groups.Oral administration of boldine and laurolitsine attenuates periodontitis-associated alveolar bone loss, likely through differential modulation of cytokine networks and osteoclastogenic signaling. These findings support their potential as host-modulating agents in the management of periodontitis.